Following a two-year investigation, the Federal Trade Commission plans to file lawsuits against the largest three pharmacy-benefit managers, or PBMs, over their tactics for negotiating prices for drugs including insulin, taking aim at the business practices related to rebates brokered with drug manufacturers, a person familiar with the matter told The Wall Street Journal’s Liz Essley Whyte and Anna Wilde Mathews. The three largest PBMs – UnitedHealth Group’s (UNH) OptumRx, Cigna’s (CI) Express Scripts and CVS Health’s (CVS) Caremark – each share a parent with a large health insurer and handle roughly 80% of U.S. prescriptions, the Journal noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- JPMorgan says FTC report lacks ‘teeth to meaningfully change PBM landscape’
- FTC releases interim staff report on pharmacy benefit managers
- WSJ investigation finds Medicare Advantage insurers made false diagnoses
- William Blair downgrades Amedisys on tighter takeover spread
- Amedisys, UnitedHealth to divest home health care centers to VitalCaring